<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001673277</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0000818686</issuerCik>
<issuerName>Teva Pharmaceutical Industries Limited</issuerName>
<secFileNumber>001-16174</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">124 Dvora HaNevi'a Street</street1>
<city xmlns="http://www.sec.gov/edgar/common">Tel Aviv </city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">L3</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">6944020</zipCode>
</issuerAddress>
<issuerContactPhone>972-3-9148213</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Francis Richard D.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Officer</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Societe Generale Private Banking (Monaco)</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">11 Avenue De Grande-Bretagne</street1>
<city xmlns="http://www.sec.gov/edgar/common">Monaco</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">O9</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">98000</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>250000</noOfUnitsSold>
<aggregateMarketValue>10742500</aggregateMarketValue>
<noOfUnitsOutstanding>1164426972</noOfUnitsOutstanding>
<approxSaleDate>11/10/2026</approxSaleDate>
<securitiesExchangeName>NYSE</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>02/16/2024</acquiredDate>
<natureOfAcquisitionTransaction>Vesting of restricted share units</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Teva Pharmaceutical Industries Limited</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>87125</amountOfSecuritiesAcquired>
<paymentDate>02/16/2024</paymentDate>
<natureOfPayment>Compensation</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>03/05/2024</acquiredDate>
<natureOfAcquisitionTransaction>Vesting of restricted share units</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Teva Pharmaceutical Industries Limited</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>36170</amountOfSecuritiesAcquired>
<paymentDate>03/05/2024</paymentDate>
<natureOfPayment>Compensation</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>02/19/2025</acquiredDate>
<natureOfAcquisitionTransaction>Vesting of restricted share units</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Teva Pharmaceutical Industries Limited</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>86149</amountOfSecuritiesAcquired>
<paymentDate>02/19/2025</paymentDate>
<natureOfPayment>Compensation</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>03/04/2025</acquiredDate>
<natureOfAcquisitionTransaction>Vesting of restricted share units</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Teva Pharmaceutical Industries Limited</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>35889</amountOfSecuritiesAcquired>
<paymentDate>03/04/2025</paymentDate>
<natureOfPayment>Compensation</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>03/05/2025</acquiredDate>
<natureOfAcquisitionTransaction>Vesting of restricted share units</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Teva Pharmaceutical Industries Limited</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>4667</amountOfSecuritiesAcquired>
<paymentDate>03/05/2025</paymentDate>
<natureOfPayment>Compensation</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<noticeSignature>
<noticeDate>11/10/2026</noticeDate>
<planAdoptionDates>
<planAdoptionDate>06/15/2026</planAdoptionDate>
</planAdoptionDates>
<signature>/s/ Richard D. Francis</signature>
</noticeSignature>
</formData>
</edgarSubmission>
